Implanted radiation device cuts brain tumor recurrence: 5 study notes

Ella Jeffries / beckershospitalreview - An implanted radiation device has improved tumor control and overall survival compared with standard radiation therapy in patients with newly diagnosed operable brain metastases, according to phase 3 clinical trial data presented May 30 at the American So…

AI Summary: Clinical trial data show an implanted "tile" radiation device placed at resection sites lowers local recurrence risk for patients with brain metastases. The approach provides a targeted, intraoperative boost that shortens treatment timelines — and gives surgeons one more tool to argue they cured something before the tumor disagreed.

#medicaldevices #oncology #cancerresearch #clinicaltrials #neuroscience

28 days / oncodaily

29 days / oncodaily

5 wks / oncodaily


Back to Top / Sat, June 6, 2026, 5:21 am / permalink 24905 / 5 stories in 5 wks /




Related Stories


SBRT extends progression‑free survival in oligometastatic breast cancer / 7 wks

Ultra‑sensitive ctDNA blood test could personalize breast cancer care for older women / 3 months

First‑in‑human glioblastoma immunotherapy yields promising PFS benefit / 9 hrs

Multi‑antigen T cells show early activity in pediatric brain cancers / 7 days

First‑in‑human IL‑2 cytokine factory trial shows early promise in ovarian cancer / 1 month

Personalized glioblastoma vaccine shows early promise in trials / 1 month

Small study reports 100% one‑year survival after lung transplant / 20 hrs

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Rural Health, Diabetes, Health IT, Medical Devices and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.